Week48 Cognitive Improvement in HAND After Switch to HAART Based on CHARTER Score +3
Neuro+3 is a pilot open-label study which evaluates the cognitive status in patients with HAND (HIV-Associated Neurocognitive Disorders), despite effective ARV therapy for more than one year. After inclusion, the initial ARV treatment (T) was changed to a new combination with enhanced Charter score (+3) and the same battery of cognitive tests was planned after…